SCHEMBL16626772

SCHEMBL16626772

CNCc1cn(S(=O)(=O)c2cccc(F)c2)c2cc(Nc3ccc(Cl)cc3Cl)cnc12

nearest known ligand 0.39

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 13/20 0.39
DRD2 P14416 1/20 0.35
NFE2L2 Q16236 1/20 0.35
CCR1 P32246 1/20 0.35
CCR2 P41597 1/20 0.35
BRD4 O60885 1/20 0.33
ALOX15 P16050 1/20 0.33
FBP1 P09467 1/20 0.33
FGFR4 P22455 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16619562 0.99 HTR6 (0.39) HTR6DRD2NFE2L2CCR1CCR2
SCHEMBL16626666 0.93 HTR6 (0.39) HTR6DRD2NFE2L2CCR1CCR2
Hydrochloric Acid SCHEMBL16619579 0.92 HTR6 (0.38) HTR6DRD2NFE2L2CCR1CCR2
SCHEMBL17971593 0.87 HTT (0.37) HTR6FBP1MAPTHTTNPSR1
SCHEMBL16626793 0.87 HTR6 (0.38) HTR6DRD2NFE2L2BRD4FGFR4
SCHEMBL16626795 0.87 NAMPT (0.39) HTR6BRD4FBP1HTT
Hydrochloric Acid SCHEMBL16618939 0.87 HTT (0.37) HTR6FBP1MAPTHTTNPSR1
SCHEMBL16626682 0.86 HTR6 (0.33) HTR6BRD4
Hydrochloric Acid SCHEMBL16619768 0.86 HTR6 (0.38) HTR6DRD2NFE2L2BRD4FGFR4
Hydrochloric Acid SCHEMBL16618910 0.86 NAMPT (0.39) HTR6DRD2BRD4FBP1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP claimed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME GIPR, PGC, SI HTR6 166/4885DRD2 2007/4885NFE2L2 1510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.